Online evaluation for Wegovy (semaglutide) for chronic weight management
Wegovy (semaglutide) is an FDA-approved, once-weekly semaglutide injection for chronic weight management, prescribed by a Regenics provider. Take a short health questionnaire. A licensed Regenics provider reviews your answers and decides whether Wegovy is right for you, based on your history and goals. Available nationwide by telehealth, with optional in-clinic visits in Tarzana, CA.
FDA-approved
FDA-approved for chronic weight management in eligible adults, used alongside a reduced-calorie diet and more physical activity.
How Wegovy works
Semaglutide acts like a hormone your gut already releases after meals. It slows digestion and quiets hunger between meals, so most patients eat less without forcing it.
How Wegovy is dosed
Your dose starts low at 0.25mg weekly and steps up over your first months so your body can adapt.
Clinical results
In a 68-week clinical study, adults on semaglutide 2.4mg lost an average of 15% of their body weight, used alongside diet and activity.
¹Clinical trial context: average weight loss outcomes vary by study population and eligibility criteria. Results are not guaranteed and depend on medical profile, titration, and adherence.
Based on your provider's likely recommendation and trial averages for that protocol after one year
Starting weight: 260 lbs
You could lose:
39 pounds
Wegovy is an FDA-approved, once-weekly semaglutide injection for chronic weight management in eligible adults, used alongside a reduced-calorie diet and more physical activity. Semaglutide is a GLP-1 receptor agonist, the same active ingredient as Ozempic which regulates appetite and how full you feel. It slows how fast your stomach empties, so you feel full sooner and stay full longer. Your dose starts low and steps up over your first months so your body can adapt.
Medication name: Wegovy (semaglutide)
Active ingredient: semaglutide
Drug type: GLP-1 receptor agonist
How it's taken: Once-weekly injection using a prefilled pen
Regenics takes a clinician-guided approach to chronic weight management. Wegovy (semaglutide) is prescribed only when medically appropriate and as part of a structured care plan that includes eligibility screening, individualized dose titration, and ongoing monitoring. Licensed clinicians evaluate whether treatment is indicated, support tolerability during dose escalation, and adjust dosing based on response and safety considerations.
Regenics structures care as a monthly prescription-only subscription designed to support continuity, follow-up, and clinician-guided dose adjustments over time.
Eligibility is determined through clinician evaluation rather than automated approval
Care is structured around long-term weight management goals rather than one-time prescribing
Wegovy (semaglutide) dosing follows a structured titration approach, with adjustments based on response and tolerability
Tarzana clinic and telehealth options available
Follow-up appointments support monitoring of side effects and overall treatment response
Your care is managed by the same licensed Regenics providers throughout your treatment. Unlike platforms where patients may see a different provider each time, Regenics is designed to provide continuity of care. They get to know your health history, monitor your progress, adjust your treatment when needed, and provide personalized care every step of the way.
Philip Marks, MSN, FNP-C
Philip is a board-certified family nurse practitioner with more than 14 years of clinical experience. He earned his MSN from UCLA and a Post-Master's FNP-C from UC Irvine. At Regenics, he specializes in hormone optimization, weight management, and peptide and regenerative therapies.
Paula Barash, FNP-C
Paula Barash, is a board-certified family nurse practitioner with over 6 years of nursing experience. She earned her Master of Science in Nursing from West Coast University, with a clinical background in perioperative and surgical care. At Regenics, she focuses on weight management, hormone optimization, and medical aesthetics.
Joanna Stuppler, MSN, NP-C
Joanna Stuppler, is a board-certified nurse practitioner with over 10 years of clinical experience spanning critical care, transplant surgery, internal medicine, and weight loss. She earned her Master of Science in Nursing from the University of Texas at Arlington. At Regenics, she focuses on weight management and preventive care.
Anna Gryunshpan, FNP
Anna is a family nurse practitioner with over 9 years of experience in aesthetic medicine. At Regenics, she specializes in injectables, skin rejuvenation, body contouring, weight management, hormone optimization, and peptide therapy. She also serves as a nurse educator to RNs, NPs, and PAs.
Online consultation and eligibility assessment
Begin with a clinician-led evaluation to determine whether Wegovy (semaglutide) is medically appropriate based on your health profile and weight management goals. This review includes BMI criteria, weight-related conditions, prior treatment history, and relevant safety considerations. If treatment is appropriate, your clinician will outline dosing strategy, follow-up cadence, and expectations for monitoring.
A provider reviews and prescribes
If eligible, your Regenics clinician develops a structured care plan that includes gradual dose titration and ongoing monitoring. The plan includes injection scheduling, escalation timing, and individualized guidance designed to support tolerability and adherence. Dose adjustments are made based on clinical response and safety considerations to help maintain consistency over time.
Ongoing monitoring and follow-up support
Care continues through a monthly prescription-only subscription structured to support continuity. Follow-up appointments and clinician-guided dose titration help monitor tolerability, review side effects, and adjust dosing when appropriate. If additional services are recommended beyond the prescription-only subscription, timing and any applicable fees are explained in advance so you can make informed decisions.
These are individual patient experiences, not typical results. Individual results vary.
If Semaglutide isn't the right fit, your Regenics provider can discuss other GLP-1 weight loss medications, including compounded Tirzepatide or brand-name, FDA approved Zepbound. What your provider recommends is based on your medical history and your goals.
Brand-name · FDA-approved
Costs more than the compounded options, with FDA approval tied to that exact formulation
Compounded · once-weekly injection
Often the higher-efficacy option. Some providers start here, especially with a higher starting BMI or a plateau on a previous GLP-1
¹ Clinical trial data: In the 68-week STEP 1 study, participants receiving semaglutide 2.4 mg in combination with diet and exercise achieved an average body weight reduction of approximately 14.9%. Individual results vary.
² Long-term outcomes: In the SELECT cardiovascular outcomes trial in adults with overweight or obesity and established cardiovascular disease, semaglutide treatment was associated with a 20% relative reduction in major adverse cardiovascular events compared with placebo. Relative risk reduction differs from absolute risk reduction. Individual results vary.
³ Pricing: Pricing shown reflects the prescription-only monthly subscription. Medication cost is separate and paid through the pharmacy. Pricing may vary by clinical eligibility.
